Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

CorMedix (CRMD) EBIAT (2016 - 2025)

CorMedix (CRMD) has disclosed EBIAT for 14 consecutive years, with $108.6 million as the latest value for Q3 2025.

  • Quarterly EBIAT rose 4009.63% to $108.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $131.2 million through Dec 2025, up 831.93% year-over-year, with the annual reading at $1.7 million for FY2025, 109.48% up from the prior year.
  • EBIAT hit $108.6 million in Q3 2025 for CorMedix, up from $2.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $108.6 million in Q3 2025 to a low of -$14.5 million in Q1 2024.
  • Historically, EBIAT has averaged $1.3 million across 5 years, with a median of -$7.4 million in 2021.
  • Biggest five-year swings in EBIAT: tumbled 64.15% in 2022 and later soared 4009.63% in 2025.
  • Year by year, EBIAT stood at -$7.8 million in 2021, then fell by 5.34% to -$8.2 million in 2022, then decreased by 18.73% to -$9.7 million in 2023, then soared by 238.18% to $13.5 million in 2024, then soared by 706.3% to $108.6 million in 2025.
  • Business Quant data shows EBIAT for CRMD at $108.6 million in Q3 2025, $2.0 million in Q2 2025, and $20.6 million in Q1 2025.